ABAXIS, Inc. (ABAX) Expected to Announce Earnings of $0.29 Per Share
Analysts expect ABAXIS, Inc. (NASDAQ:ABAX) to announce earnings of $0.29 per share for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for ABAXIS’s earnings. The lowest EPS estimate is $0.27 and the highest is $0.30. ABAXIS posted earnings of $0.34 per share in the same quarter last year, which would suggest a negative year over year growth rate of 14.7%. The firm is expected to report its next earnings report after the market closes on Tuesday, October 24th.
On average, analysts expect that ABAXIS will report full-year earnings of $1.15 per share for the current financial year, with EPS estimates ranging from $1.10 to $1.20. For the next financial year, analysts expect that the firm will post earnings of $1.33 per share, with EPS estimates ranging from $1.23 to $1.46. Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow ABAXIS.
ABAXIS (NASDAQ:ABAX) last issued its quarterly earnings results on Thursday, July 27th. The medical research company reported $0.28 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.33 by ($0.05). The firm had revenue of $58.26 million during the quarter, compared to analysts’ expectations of $60.37 million. ABAXIS had a return on equity of 10.85% and a net margin of 14.12%. ABAXIS’s revenue for the quarter was up 1.0% on a year-over-year basis. During the same period in the previous year, the company earned $0.30 earnings per share.
A number of equities research analysts have weighed in on ABAX shares. Stifel Nicolaus reaffirmed a “hold” rating and set a $48.00 target price on shares of ABAXIS in a research report on Friday, July 14th. Zacks Investment Research lowered ABAXIS from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. BidaskClub lowered ABAXIS from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 3rd. Finally, Bank of America Corporation reaffirmed an “underperform” rating and set a $42.00 target price on shares of ABAXIS in a research report on Wednesday, August 23rd. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $48.63.
Shares of ABAXIS (NASDAQ ABAX) opened at 47.05 on Tuesday. The stock has a market capitalization of $1.07 billion, a PE ratio of 33.23 and a beta of 0.82. ABAXIS has a 52 week low of $43.66 and a 52 week high of $55.95. The company has a 50-day moving average price of $45.45 and a 200 day moving average price of $48.13.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/24/abaxis-inc-abax-expected-to-announce-earnings-of-0-29-per-share.html.
Several large investors have recently made changes to their positions in the company. Kayne Anderson Rudnick Investment Management LLC increased its holdings in shares of ABAXIS by 5.8% in the 2nd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 3,132,117 shares of the medical research company’s stock valued at $166,065,000 after acquiring an additional 171,541 shares during the period. BlackRock Inc. increased its holdings in shares of ABAXIS by 132,779.9% in the 1st quarter. BlackRock Inc. now owns 2,689,490 shares of the medical research company’s stock valued at $130,442,000 after acquiring an additional 2,687,466 shares during the period. Vanguard Group Inc. increased its holdings in shares of ABAXIS by 0.9% in the 2nd quarter. Vanguard Group Inc. now owns 1,963,755 shares of the medical research company’s stock valued at $104,119,000 after acquiring an additional 16,676 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of ABAXIS by 1.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 672,229 shares of the medical research company’s stock valued at $35,642,000 after acquiring an additional 10,991 shares during the period. Finally, State Street Corp increased its holdings in shares of ABAXIS by 1.0% in the 2nd quarter. State Street Corp now owns 569,671 shares of the medical research company’s stock valued at $30,203,000 after acquiring an additional 5,672 shares during the period. Institutional investors and hedge funds own 97.28% of the company’s stock.
ABAXIS Company Profile
Abaxis, Inc is a developer, manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements. The Company markets and sells its products around the world through independent distributors and direct sales force.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ABAXIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABAXIS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.